Review identifies serotonin overactivity as a cause of Hypoactive Sexual Desire Disorder (HSDD), highlighting bremelanotide and flibanserin as treatment options.
Background
The neurobiology of female sexual response is complex, involving a delicate balance between excitatory and inhibitory neurotransmitter systems. Excitatory pathways are primarily modulated by dopamine, norepinephrine, oxytocin, and melanocortins, while inhibitory pathways are regulated by serotonin, opioids, and endocannabinoids. In Hypoactive Sexual Desire Disorder (HSDD), it is hypothesized that an overactive serotonergic system suppresses the dopaminergic system, leading to decreased sexual desire. This imbalance makes it difficult for excitatory systems to be activated by sexual cues. Current treatment strategies aim to correct this neurochemical imbalance. This review explores pharmacologic agents that target the central serotonin system to restore the balance and improve symptoms of HSDD, moving beyond purely hormonal models of female sexual dysfunction.
Study Design
This paper is a narrative review of the existing scientific literature. The authors conducted searches of the Medline database to identify relevant articles concerning the role of serotonin in female sexual function and the treatment of Hypoactive Sexual Desire Disorder (HSDD). The review synthesized findings from both preclinical studies and clinical trials to elucidate the neurobiological mechanisms underlying HSDD, with a specific focus on the serotonergic system. It evaluated centrally acting drugs, including bremelanotide, bupropion, buspirone, and the approved medication flibanserin, as potential therapeutic interventions.
Results
The review concluded that overactive serotonin activity is a putative cause of sexual dysfunction in patients with HSDD. Serotonin acts as a key inhibitory modulator of sexual desire by reducing the ability of excitatory systems, like dopamine, to respond to sexual cues. This creates a neurobiological imbalance favoring inhibition over excitation. Centrally acting drugs that modulate these pathways have been investigated as treatments.
The paper highlights that flibanserin—a multifunctional serotonin agonist and antagonist with activity as a
5-HT1Areceptor agonist and a5-HT2Areceptor antagonist—is the only drug currently approved specifically for HSDD. This dual mechanism is thought to decrease inhibitory serotonergic function while simultaneously restoring excitatory dopaminergic and noradrenergic function.
Other agents like bremelanotide (a melanocortin agonist), bupropion, and buspirone also modulate these central pathways and have been studied for their potential in treating HSDD. The central serotonin system is confirmed as a primary biochemical target for medications designed to address this condition.
Key Findings
- Overactive serotonin activity is identified as a likely cause of Hypoactive Sexual Desire Disorder (HSDD) in women.
- Serotonin is a key inhibitory modulator of sexual desire, as it decreases the activation of excitatory systems (e.g., dopamine) by sexual cues.
- Centrally acting drugs like bremelanotide, bupropion, and buspirone have been investigated as treatments for HSDD.
- Flibanserin, a 5-HT1A receptor agonist and 5-HT2A receptor antagonist, is the only drug currently approved for HSDD treatment.
- Flibanserin's mechanism is proposed to tone down inhibitory serotonergic function while restoring dopaminergic and noradrenergic function.
Why It Matters
This review reinforces the understanding that female sexual desire is not just hormonal but is deeply rooted in central nervous system neurochemistry, particularly the balance between serotonin and dopamine. For individuals exploring treatments for low libido, this highlights that interventions targeting these neurotransmitter systems, such as bremelanotide or flibanserin, are based on a sound neurobiological rationale. The paper's focus on the serotonin-dopamine axis provides a framework for understanding why certain drugs may be effective. This knowledge empowers individuals to consider centrally-acting agents that modulate neurotransmitters, rather than relying solely on hormonal therapies. While flibanserin is the only approved drug mentioned, the discussion of other compounds like bremelanotide suggests that the melanocortin pathway is also a viable and distinct target for enhancing sexual desire, offering alternative mechanisms for those who do not respond to or tolerate serotonergic agents.
TitrateLab articles covering PT-141
Written by TitrateLab, separately from the study summarized above.
